Aude Terrade
Overview
Explore the profile of Aude Terrade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Razki A, Hong E, Zerouali K, Belabbes H, Aitmouss K, Terrade A, et al.
J Clin Microbiol
. 2018 May;
56(7).
PMID: 29743304
Meningococcal epidemiology may change unpredictably, and typing of isolates is crucial for the surveillance of invasive meningococcal disease (IMD). Few data are available regarding the meningococcal epidemiology in countries of...
12.
Guiddir T, Gros M, Hong E, Terrade A, Denizon M, Deghmane A, et al.
Clin Infect Dis
. 2018 Apr;
67(8):1220-1227.
PMID: 29608658
Background: Invasive meningococcal disease (IMD) is recognized as septicemia and/or meningitis. However, early symptoms may vary and are frequently nonspecific. Early abdominal presentations have been increasingly described. We aimed to...
13.
Hong E, Barret A, Terrade A, Denizon M, Antona D, Aouiti-Trabelsi M, et al.
J Infect
. 2017 Nov;
76(2):149-158.
PMID: 29132919
Background: Neisseria meningitidis group W (NmW) belonging to the clonal complex ST-11 (NmW/cc11) spread in Europe and in France in 2000 and declined thereafter. In France, invasive meningococcal disease (IMD)...
14.
Sevestre J, Hong E, Delbos V, Terrade A, Mallet E, Deghmane A, et al.
Vaccine
. 2017 Jun;
35(32):4029-4033.
PMID: 28624305
Objectives: MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse...
15.
Hong E, Terrade A, Taha M
Hum Vaccin Immunother
. 2016 Nov;
13(3):645-648.
PMID: 27808594
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation...
16.
Antunes A, Derkaoui M, Terrade A, Denizon M, Deghmane A, Deutscher J, et al.
PLoS One
. 2016 Sep;
11(9):e0162434.
PMID: 27655040
Neisseria meningitidis is an exclusively human pathogen frequently carried asymptomatically in the nasopharynx but it can also provoke invasive infections such as meningitis and septicemia. N. meningitidis uses a limited...
17.
Belkacem N, Hong E, Antunes A, Terrade A, Deghmane A, Taha M
Antimicrob Agents Chemother
. 2016 Apr;
60(7):4023-7.
PMID: 27090179
Antibiotic susceptibility testing (AST) in Neisseria meningitidis is an important part of the management of invasive meningococcal disease. It defines MICs of antibiotics that are used in treatment and/or prophylaxis...
18.
Besbes A, Le Goff S, Antunes A, Terrade A, Hong E, Giorgini D, et al.
PLoS Pathog
. 2015 Aug;
11(8):e1005078.
PMID: 26241037
Differential modulation of NF-κB during meningococcal infection is critical in innate immune response to meningococcal disease. Non-invasive isolates of Neisseria meningitidis provoke a sustained NF-κB activation in epithelial cells. However,...
19.
Lemee L, Hong E, Etienne M, Deghmane A, Delbos V, Terrade A, et al.
PLoS One
. 2014 Sep;
9(9):e107240.
PMID: 25247300
The prevention of meningococcal disease may be improved by recombinant vaccines such as 4CMenB and rLP2086 that target the factor H binding protein (fHbp), an immunogenic surface component of Neisseria...
20.
Terrade A, Collard J, Nato F, Taha M
Trans R Soc Trop Med Hyg
. 2013 May;
107(7):460-1.
PMID: 23687106
Background: Epidemics of meningococcal meningitis occur periodically in the African 'meningitis belt' and are mainly, but not only, due to serogroup A. Methods: We tested a dipstick as a rapid...